Vandetinib is a novel, selective dual inhibitor of the vascular endothelial growth factor receptor pathway and epidermal growth factor receptor pathway. Phase I studies have established that it is suitable for once-daily oral dosing at a dose of up to 300 mg. Vandetinib has been tested in multiple randomized controlled phase II clinical studies, which have established that this is a promising new targeted agent for the treatment of patients with advanced non-small cell lung cancer and which also support the potential role of vandetinib administered concurrently with chemotherapy. Further testing of its role in lung cancer is in ongoing.
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(J Thorac Oncol. 2008;3: Suppl 2, S128 -S130) V andetinib (Zactima, ZD6474, AstraZeneca, Wilmington, Delaware) is a novel, selective inhibitor of vascular endothelial growth factor receptors (VEGFRs) 2 and 3, epidermal growth factor receptor (EGFR), and RET kinases. In preclinical studies, it was found to be a potent inhibitor of tumorinduced angiogenesis and of the growth of multiple epithelial tumor models, including Calu-6 (lung), PC-3 (prostate), LoVo (colon), MDA-MB-231 (breast), SKOV-3 (ovarian), and A431 (vulva). 1 More extensive laboratory studies in human lung cancer cell line models demonstrated that vandetinib is comparable to other EGFR inhibitors, including gefitinib(Iressa, AstraZeneca, Wilmington, Delaware) and erlotinib (Tarceva, Genentech, South San Francisco, CA) in causing regression of established HCC827 xenografts. 2 Nevertheless, in contrast to gefitinib and erlotinib, vandetinib also was effective in cell lines with acquired resistance to EGFR inhibition (T790M mutation) and in cell lines with overexpression of K-ras.
Two phase I clinical trials with vandetinib established that daily oral doses up to 300 mg were generally well tolerated, with the most common adverse events consisting of mild to moderate rash, diarrhea, and asymptomatic QTc prolongation. 3, 4 Pharmacokinetic studies 4 indicated a terminal half-life of approximately 120 hours, which was suitable for a once-daily oral dosing schedule. In the study by Tamura et al., 4 the observation of objective responses in four of nine Japanese patients with advanced non-small cell lung cancer (NSCLC) suggested single-agent efficacy but also raised the logical question of whether this new agent was acting simply as another EGFR inhibitor or whether VEGFR inhibition contributed to its efficacy. Furthermore, since the concurrent use of EGFR inhibitors and chemotherapy has not been an effective strategy thus far, the question remains of whether this novel dual inhibitor will suffer the same dilemma.
The first phase II studies were designed to answer these questions. Trial 3 was a phase II, randomized, double-blind comparison of vandetinib and gefitinib in previously treated patients with advanced or metastatic NSCLC (Figure 1 ). After disease progression to the initial randomized treatment (part A) and a 4-week no treatment washout, patients were eligible to receive the alternate treatment in a blinded manner (part B). Part A of the study was designed to have a 75% power to detect a 33% increase in progression-free survival at a significance level of p Ͻ 0.02. Part B was designed to obtain data regarding cross-resistance. Eligibility criteria included patients with disease progression after first-line platinum-based chemotherapy and not more than one additional cytotoxic second-line regimen, a performance status of 0 to 2, adequate organ function, and no prior exposure to an EGFRtargeted agent. One hundred sixty-eight patients were entered into part A of the study. The two arms were well balanced with respect to median age, sex, performance status, smoking history, histologic subtype, and stage IIIB versus stage IV.
The trial achieved its primary end point. Patients in the vandetinib arm achieved a statistically significant improvement in progression-free survival compared with the gefitinib arm with a hazard ratio of 0.69 (95% confidence interval, 0.50 -0.96) and a 2-sided p value of 0.025. In part B of the study, vandetinib achieved disease control in 16 of 37 patients (43%) who were initially treated with gefitinib. In contrast, gefitinib achieved disease control in only 7 of 29 patients (24%) initially treated with vandetinib.
Rash, diarrhea, and nausea were similar in the two arms of the study in part A and were generally mild. Headache, dizziness, hypertension, and QT-related events were more common in the vandetinib arm than in the gefitinib arm.
Trial 6 consisted of a run-in feasibility study of docetaxel combined with vandetinib followed by a 3-armed phase II randomized trial of docetaxel, 75 mg/m 2 every 3 weeks alone or combined with 100 mg per day or 300 mg per day of vandetinib 5 ( Figure 2) . Eligibility criteria were similar to trial 3 except patients may have received only first-line platinum-based chemotherapy. Progression-free survival was again the primary study end point. One hundred twenty-seven patients were entered into the trial. Both vandetinib arms produced an improvement in progression-free survival compared with the docetaxel control arm, but only the 100-mg dose level of vandetinib combined with docetaxel achieved the study end point, with a hazard ratio of 0.64 (95% confidence interval, 0.38 -1.05). Adverse effects, including rash, diarrhea, nausea or vomiting, hypertension, and QT-related events, were mildly increased in the 100 mg of vandetinib plus docetaxel arm compared with docetaxel alone (40% versus 24%, 38% versus 27%, 31% versus 24%, 7% versus 2%, and 12% versus 5%, respectively) and moderately to unacceptably increased in the 300 mg of vandetinib plus docetaxel arm (46%, 50%, 34%, 9%, and 16%, respectively).
These two trials establish that vandetinib is a promising new targeted agent for the treatment of patients with advanced NSCLC. Trial 3 confirms the single-agent activity of this agent and that its efficacy is at least partly mediated through its VEGR inhibitory property. Combined EGFR and VEGFR inhibition with vandetinib produced a better progression-free survival compared with EGFR inhibition alone with gefitinib. The fact that the disease control rate in part B of the study was greater with vandetinib after gefitinib than it was with gefitinib after vandetinib suggests that the improved effectiveness of vandetinib in part A of the study derived, at least in part, from its VEGFR inhibition. The reduced activity of gefitinib after vandetinib in part B compared with gefitinib in vandetinib-naive patients in part A strongly suggests that vandetinib is an effective EGFR inhibitor as well. These observations are currently under investigation in a definitive, prospective, randomized, double-blind, international clinical trial of vandetinib versus erlotinib.
Trial 6 strongly supports the potential role of vandetinib administered concurrently with chemotherapy. Not only was toxicity reduced at the 100-mg dose compared with the 300-mg dose of vandetinib combined with docetaxel, but the response rate and progression-free survival were somewhat better as well. Although not proven by this study, this differential effect suggests that the reduced EGFR inhibition that occurred at the 100-mg dose compared with the 300-mg dose allowed beneficial interaction between vandetinib's VEGFR inhibition and chemotherapy and that this beneficial interaction was partially overcome by increased EGFR inhibition at the 300-mg dose level. These observations are also currently under investigation in a definitive, prospective, randomized, double-blind, international clinical trial of docetaxel combined with vandetinib, 100 mg daily, versus docetaxel combined with placebo.
